Home - Invivoscribe

Invivoscribe-Shop-Product-Availability-Key-1920×160-Image-2x-001

Invivoscribe-Shop-Product-Availability-Key-Image-2x-002

All Products

Cat #: A3100020
BCR/ABL e1.1-a3.1 – Unlabeled
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: 40850210
BCR/ABL b3a2 RNA Dilution Set
OVERVIEW The BCR/ABL b3a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b3a2 positive and BCR/ABL negative cell li...
View Product
Cat #: 40850310
BCR/ABL b2a2 RNA Dilution Set
OVERVIEW The BCR/ABL b2a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b2a2 positive and BCR/ABL negative cell li...
View Product
Cat #: A3100030
BCR/ABL b2.1-a3.1 – Unlabeled
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: 23090070
BCL2/JH Tube C – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 14120020
FLT3 Mutation Assay MegaKit – Gel Detection
BACKGROUND: Acute myeloid leukemia (AML) in general has a poor prognosis. Recent studies have described mutation of the FLT3 (fms-like tyrosine kinase...
View Product
Cat #: 24120010
FLT3 ITD Master Mix – Unlabeled
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 24120011
FLT3 ITD Master Mix – 6FAM & HEX
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: 24120031
FLT3 D835 Master Mix – 6FAM
Master mixes are components of complete assays. Master mixes are composed of a buffered magnesium solution, deoxynucleotides, and multiple primers tha...
View Product
Cat #: A3100061
BCR/ABL, e1.2-a3.2 – HEX
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: A3100051
BCR/ABL, e1.2-a2.2 – HEX
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: 92060011
IdentiClone^® TCRD Gene Clonality Assay – ABI Fluorescence Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: 92060010
IdentiClone^® TCRD Gene Clonality Assay – Gel Detection
Rearrangements of the antigen receptor genes occur during ontogeny in B and T lymphocytes. These gene rearrangements generate products that are uniq...
View Product
Cat #: A3100101
BCR/ABL, b3.2-a3.2 – 6FAM
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: A3100081
BCR/ABL, b2.2-a3.2 – 6FAM
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: A3100071
BCR/ABL, b2.2-a2.2 – 6FAM
This product targets the human BCR/ABL fusion gene. ...
View Product
Cat #: 13100020
BCR/ABL t(9;22) Translocation Assay MegaKit – Gel Detection
SUMMARY: BCR/ABL translocations are associated with a variety of hematologic malignancies. These reciprocal t(9;22)(q34;ql1) chromosomal rearrangement...
View Product
Cat #: 12060011
TCRD Gene Clonality Assay – ABI Fluorescence Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 12060010
TCRD Gene Clonality Assay – Gel Detection
SUMMARY: Invivoscribe’s Gene Rearrangement and Translocation Assays represent a new approach to PCR-based clonality testing. These standardized ...
View Product
Cat #: 13100041
BCR/ABL t(9;22) Translocation Assay MegaKit – ABI Fluorescence Detection
SUMMARY: BCR/ABL translocations are associated with a variety of hematologic malignancies. These reciprocal t(9;22)(q34;ql1) chromosomal rearrangement...
View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Territory

Detection

Regulatory Classification

Locus Target

Application

Product Type

Box Type

Design

Size

All Products

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Coming Soon

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL